seralutinib
GB002 · PK10571 Small Molecule Target: PDGFR, CSF1R, c-KIT
Gossamer Bio
Most recent annual filing: 2026-03-15
- corporate update3Q 2026corporate update, 3Q 2026, routine
- RT234 Inhaled Vardenafil trial start2027RT234 Inhaled Vardenafil trial start, 2027, routine
- 2030 Notes corporate updateMar 2, 20272030 Notes corporate update, Mar 2, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
vardenafil
RT234 Small Molecule Target: PDE5
Biotech Distilled coverage (8)
- 2026-08-22 UPDATE: Gossamer Bio (GOSS) - Somebody Just Underwrote the Hail Mary 🔒 Paid
- 2026-08-14 UPDATE: Gossamer Bio (GOSS) - The Debt Wall Didn’t Move to 2030. It Moved to March.
- 2026-07-28 UPDATE: Gossamer Bio (GOSS) - The Zombie Gets a Filing Path
- 2026-05-19 UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity
- 2026-05-16 UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives 🔒 Paid
- 2026-03-22 UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral
- 2026-03-01 UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut 🔒 Paid
- 2026-02-03 Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.